Innovators in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies have joined TMC's Accelerator for Cancer Therapeutics. Photo courtesy TMC.

Texas Medical Center Innovation has named more than 50 health care innovators to the fifth cohort of its Accelerator for Cancer Therapeutics (ACT).

The group specializes in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies, according to a statement from TMC.

During the nine-month ACT program, participants will enjoy access to a network of mentors, grant-writing support, chemistry resources, and the entrepreneur-in-residence program. The program is designed to equip participants with the ability to secure investments, develop partnerships, and advance the commercialization of cancer therapeutics in Texas.

“With over 35 million new cancer cases predicted by 2050, the urgency to develop safer, more effective, and personalized treatments cannot be overstated,” Tom Luby, chief innovation officer at Texas Medical Center, said in a news release.

Members of the new cohort are:

  • Alexandre Reuben, Kunal Rai, Dr. Cassian Yee, Dr. Wantong Yao, Dr. Haoqiang Ying, Xiling Shen, and Zhao Chen, all of the University of Texas MD Anderson Cancer Center
  • Dr. Andre Catic and Dr. Martin M. Matzuk, both of the Baylor College of Medicine
  • Cynthia Hu and Zhiqiang An, both of UTHealth Houston
  • Christopher Powala, Aaron Sato, and Mark de Souza, all of ARespo Biopharma
  • Daniel Romo, Dr. Susan Bates, and Ken Hull, all of Baylor University
  • Eugene Sa & Minseok Kim, both of CTCELLS
  • Gomika Udugamasooriya and Nathaniel Dawkins, both of the University of Houston
  • Dr. Hector Alila of Remunity Therapeutics
  • Iosif Gershteyn and Victor Goldmacher, both of ImmuVia
  • João Seixas, Pedro Cal, and Gonçalo Bernardes, all of TargTex
  • Ken Hsu and Yelena Wetherill, both of the University of Texas at Austin
  • Luis Martin and Dr. Alberto Ocaña, both of C-Therapeutics
  • Dr. Lynda Chin, Dr. Keith Flaherty, Dr. Padmanee Sharma, James Allison, and Ronan O’Hagan, all of Project Crest/Apricity Health
  • Michael Coleman and Shaker Reddy, both of Metaclipse Therapeutics
  • Robert Skiff and Norman Packard, both of 3582.ai
  • Rolf Brekken, Uttam Tambar, Ping Mu, Su Deng, Melanie Rodriguez, and Alexander Busse, all of UT Southwestern Medical Center
  • Ryan Swoboda and Maria Teresa Sabrina Bertilaccio, both of NAVAN Technologies
  • Shu-Hsia Chen and Ping-Ying Pan, both of Houston Methodist
  • Thomas Kim, Philipp Mews, and Eyal Gottlieb, all of ReEngage Therapeutics
The ACT launched in 2021 and has had 77 researchers and companies participate. The group has collectively secured more than $202 million in funding from the NIH, CPRIT and venture capital, according to TMC.
Texas Medical Center Innovation won a Prix Galien Award, which has been described as being comparable to the Nobel Prize for the life science community. Photo by Natalie Harms/InnovationMap

Houston's Texas Medical Center wins prestigious global award recognizing leaders in life science innovation

new bling

Last month, a global organization honored innovation leaders in life sciences, and the Texas Medical Center was among the recipients of the prestigious awards program.

The 18th annual Prix Galien Awards Gala awarded TMC Innovation with the win in the "Incubators, Accelerators and Equity" category. The Galien Foundation created the awards program in 1970 in honor of Galien, the father of medical science and modern pharmacology. Alongside TMC, the other winners represented biotech, digital health, startups, and more.

"We are super proud of this distinction," Tom Luby, director of TMC Innovation says at Envision 2024 last month, crediting the TMCi team and TMC leadership for the award. "We lean on a lot of advisers and experts — people who volunteer their time to work with startups. Without (them), we would not have been successful."

Luby explains that a Prix Galien Award holds a Nobel Prize level of significance for the community.

TMCi was named a finalist in August, and competed against programs from Cedars-Sinai, Mayo Foundation for Medical Education and Research, TechConnect, and more.

"The Awards Committee is honored to witness the exceptional dedication and creativity of our nominees as they turn visionary ideas into transformative solutions for patients worldwide," says Michael Rosenblatt, chair of the Prix Galien USA Awards Committee, in a news release. "Their unwavering commitment to advancing patient care is truly commendable, and we are honored to celebrate their outstanding contributions to global health."

The award is displayed at TMC Innovation's office, located in the medical center at 2450 Holcombe Blvd.

Rice University, Baylor College of Medicine, and Houston Methodist have awarded a total of $50,000 to two projects. Photo by Brandon Martin/Rice University

Houston organizations issue seed grants to fuel AI-driven equity, digital health innovation

fresh funding

Three Houston organizations have doled out seed grants for research initiatives focused on digital health and equity.

Rice University's Educational and Research Initiatives for Collaborative Health (ENRICH) office — in partnership with Baylor College of Medicine and the Houston Methodist Academic Institute — has awarded a total of $50,000 to two projects. BCM and Rice announced three other grants earlier this year.

The seed grants were deployed earlier this year at the Health Equity Workshop from Rice’s Digital Health Initiative and chaired by Momona Yamagami, an assistant professor of electrical and computer engineering at Rice.

“To achieve equitable health outcomes, a comprehensive approach is essential — one that spans all phases of digital health from technology design and development to implementation, dissemination and long-term sustainability,” says Ashutosh Sabharwal, who leads the Digital Health Initiative and serves as Rice’s Ernest Dell Butcher Professor of Engineering and a professor of electrical and computer engineering, in a news release.

Both the workshop and the grant opportunity help to allow collaboration between researchers and health care providers working on health equity research across disciplines.

“This seed grant not only fosters interdisciplinary collaborations between Rice University and the Texas Medical Center but also enables us to leverage our combined knowledge to enhance innovations in health equity and digital health, ultimately creating impactful solutions for improving patient care,” adds Sharon Pepper, executive director of ENRICH.

The two projects receiving funding, according to Rice's release, include:

  • Evaluating Equity and Community-Level Vulnerabilities in the Use of Generative Artificial Intelligence-based Symptom Checkers for Self-diagnosis — Using AI-based symptom checkers, the project aims to mitigate vulnerabilities for patients using and improve data precision specifically when it comes to patients' social and cultural differences.
  • Al-Driven ECG Analysis for Equitable Cardiovascular Risk Assessment and Prevention: Leveraging Transformer Models and Big Data to Reduce Health Disparities — Also backed by AI, this project will harness the untapped potential of electrocardiogram data for improving cardiovascular risk assessment, hopefully reducing cost and invasiveness of the standard practice of care.
CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and CE-Ventures. Photo via Getty Images

Houston biotech startup secures $10M seed round to propel cancer-fighting therapy from bench to bedside

fresh funding

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT.

The company is working on the next-generation of antibody-drug conjugates (ADC) therapeutics that process dual payloads as targeted treatments for a set of challenging cancers. The innovative treatment is based on research from UTHealth experts Dr. Kyoji Tsuchikama and Dr. Zhiqiang An.

“Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments," Torres continues.

He explains that the funding will toward advancing CrossBridge's first development candidate, CBB-120, into preclinical non-GLP toxicology studies in addition to derisking the company’s proprietary linker technology with dual-payload applications, per the release.

As a result of the raise, William McKeon, president and CEO of the Texas Medical Center, and Damir Illich, manager of life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” McKeon says in the release. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”

Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is a new biotech venture creation studio based in Texas Medical Center Helix Park. Photo courtesy of Rice

Rice University opens biotech venture studio in TMC

rapidly scaling

In its mission to amplify and advance biotech innovation, Rice University has announced its latest initiative — a new lab focused on bringing life-saving medical technologies to commercialization.

Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is a new biotech venture creation studio based in Texas Medical Center Helix Park. RBL comes on the heels of establishing the Rice Biotech Launch Pad, a biotech innovation accelerator that opened last year.

Paul Wotton, executive director of the Rice Biotech Launch Pad, co-founded RBL with his colleagues Omid Veiseh, Rice professor of bioengineering and faculty director of the Rice Biotech Launch Pad; Jacob Robinson, Rice professor of electrical and computer engineering; and Dr. Rima Chakrabarti, a physician scientist and venture capital investor with KdT Ventures.

“This is a pivotal moment for Houston and beyond,” Wotton, who serves as RBL’s managing partner, says in a news release from Rice. “Houston has rapidly emerged as a global life sciences powerhouse, blending cutting-edge research with early clinical applications at Rice and the city’s world-renowned hospital systems.

"Investors from across the nation are recognizing Houston’s potential, and with RBL, we’re building on that momentum," he continues. "We’ll not only amplify the work of the Rice Biotech Launch Pad but expand our reach across Texas, creating opportunities for biotech ventures statewide and driving growth for the biotech industry as a whole.”

Strategically located in TMC, RBL will collaborate with medical leaders, investors, corporations, and other players both in the same building and on the greater TMC campus.

“Leveraging Rice University’s Biotech Launch Pad breakthroughs and pairing it with the world-class translational infrastructure of TMC Helix Park well positions RBL to drive unprecedented advances in patient care,” William McKeon, president and CEO of the TMC, says in the release. “This partnership between academia, industry and health care is exactly what’s needed to transform medical discoveries into real-world solutions that improve lives globally.”

RBL is Rice's latest effort to bridge the gap between academia and biotech innovation, an effort led by Paul Cherukuri, Rice’s chief innovation officer, who reportedly spearheaded development of the new initiative.

“RBL is a game-changer for Rice, Houston and the global biotech community,” Cherukuri adds. “This venture not only accelerates the commercialization of our innovations but also sets a blueprint for other universities looking to maximize the real-world impact of their discoveries. By combining scientific expertise with entrepreneurial support from Day Zero together with strategic clinical partnerships in the TMC, we’re creating a model for driving large-scale biotech innovation that universities everywhere should aspire to replicate.”

Since the Rice Biotech Launch Pad was established, Motif Neurotech closed its series A round with an oversubscribed $18.75 million, the hub secured a $34.9 million grant, and a “living pharmacy” founded at the Launch Pad received industry validation.

“RBL provides a powerful platform to translate high-impact scientific discoveries into therapies that will dramatically improve patient outcomes,” Veiseh says. “Our goal is to rapidly bring Rice’s pioneering research into the clinic, delivering life-saving solutions to patients around the world.”

Meet the latest global health tech startups to get an invite to Houston from TMC Innovation. Photo via tmc.edu

12 health tech startups named to Houston accelerator's next bootcamp

onboarding

Twelve promising health tech startups have been selected for the annual bootcamp at the Texas Medical Center.

TMC's Accelerator for HealthTech selected 12 companies from around the world and across specialties for the opportunity. Following the bootcamp, TMC will move forward a selection of startups to join its accelerator.

"Houston, a thriving hub for innovation, is rapidly becoming the destination of choice for healthtech companies," reads a statement from TMC. "With the Texas Medical Center at its heart, the city offers unparalleled resources, cutting-edge research facilities, and a collaborative spirit that fosters growth. This environment not only attracts startups but also provides them with the necessary tools to navigate the complex landscape of healthcare commercialization."

Through the bootcamp, the participants will engage with advisors and industry experts, refine their business models, prepare for market entry, and have opportunities for collaboration with the TMC's member organizations.

The selected bootcamp companies, according to TMC, include:

  • Alyf, founded in Newport Beach, California, has developed a personalized cardiac care system that brings patients and providers together with real-time, AI-driven insights, enabling them to monitor, track, and improve cardiac health outcomes collaboratively.
  • Seoul, South Korea-based Deepmetrics leverages artificial intelligence to provide ICU smart care services that optimize medical device settings, such as mechanical ventilators, to reduce mortality and shorten the length of stay for critically ill patients worldwide.
  • EquityQuotient, from New York City, is a healthcare intelligence platform that automates compliance and provides actionable insights by aggregating public, private, and first-party data, using proprietary analytics to help leaders address disparities, improve outcomes, and lower care costs.
  • Also from New York City, Ethermed's AI-powered solution streamlines prior authorizations, eliminating up to 90 percent of auths and 70 percent of the labor involved. Ethermed requires no workflow changes, is fully auditable, and offers aligned incentives from a mission-driven, human-focused company.
  • Fibricheck, based in Hasselt, Belgium, transforms ordinary smartphones into regulated digital heart rhythm monitors, offering unparalleled access to cardiovascular diagnostics for patients and streamlined workflows for physicians.
  • Austin-based NearWave has developed a non-invasive, AI-powered handheld imaging device that can predict breast cancer therapy response within seven days.
  • Pragmaclin, founded in Newfoundland, Canada, developed a cutting-edge PRIMS (Parkinson’s Remote Interactive Management System) that leverages depth cameras and machine learning to monitor and assess Parkinson’s Disease symptoms, offering healthcare professionals remote and in-clinic insights to enhance treatment decisions.
  • Somnair, a Baltimore, Maryland, company, is developing a non-invasive neurostimulation oral appliance for treating obstructive sleep apnea, offering a sleek, retainer-sized device that provides an effective alternative to CPAP or invasive surgery for millions of patients.
  • Vancouver, Canada-headquartered Total Flow Medical is developing solutions to enhance the quality of care and life for patients requiring the use of a heart-lung machine during surgery or life support.
  • Tympulse, hailing from Dublin, Ireland, is commercializing TympanoColl, an innovative and disruptive solution for eardrum (Tympanic Membrane) repair in an outpatient setting through the ear canal.
  • Perth, Australia-based Vital Trace is developing a continuous lactate monitor for real-time, accurate detection of fetal distress.
  • New York City's WorkUp is a healthcare-specific talent pipeline management platform that connects students with tailored resources for their clinical career journey, providing personalized support as their needs evolve.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston space tech companies land $25 million from Texas commission

Out Of This World

Two Houston aerospace companies have collectively received $25 million in grants from the Texas Space Commission.

Starlab Space picked up a $15 million grant, and Intuitive Machines gained a $10 million grant, according to a Space Commission news release.

Starlab Space says the money will help it develop the Systems Integration Lab in Webster, which will feature two components — the main lab and a software verification facility. The integration lab will aid creation of Starlab’s commercial space station.

“To ensure the success of our future space missions, we are starting with state-of-the-art testing facilities that will include the closest approximation to the flight environment as possible and allow us to verify requirements and validate the design of the Starlab space station,” Starlab CEO Tim Kopra said in a news release.

Starlab’s grant comes on top of a $217.5 million award from NASA to help eventually transition activity from the soon-to-be-retired International Space Station to new commercial destinations.

Intuitive Machines is a space exploration, infrastructure and services company. Among its projects are a lunar lander designed to land on the moon and a lunar rover designed for astronauts to travel on the moon’s surface.

The grants come from the Space Commission’s Space Exploration and Aeronautics Research Fund, which recently awarded $47.7 million to Texas companies.

Other recipients were:

  • Cedar Park-based Firefly Aerospace, which received $8.2 million
  • Brownsville-based Space Exploration Technologies (SpaceX), which received $7.5 million
  • Van Horn-based Blue Origin, which received $7 million

Gwen Griffin, chair of the commission, says the grants “will support Texas companies as we grow commercial, military, and civil aerospace activity across the state.”

State lawmakers established the commission in 2023, along with the Texas Aerospace Research & Space Economy Consortium, to bolster the state’s space industry.

Houston experts: Can AI bridge the gap between tech ambitions and market realities?

guest column

Despite successful IPOs from the likes of Ibotta, Reddit and OneStream, 2024 hasn’t provided the influx of capital-raising opportunities that many late-stage tech startups and venture capitalists (VCs) have been waiting for. Since highs last seen in 2021—when 90 tech companies went public—the IPO market has been effectively frozen, with just five tech IPOs between January and September 2024.

As a result, limited partners have not been able to replenish investments and redeploy capital. This shifting investment landscape has VCs and tech leaders feeling stuck in a holding pattern. Tech leaders are hesitant to enter the public markets because valuations are down 30 percent to 40 percent from 2021, which is also making late-stage fundraising more challenging. After all, longer IPO timelines mean fewer exit opportunities for VCs and reduced capital from institutional investors who are turning toward shorter-term investments with more liquid exit options.

Of course, there’s always an exception. And in the case of a slowed IPO market, a select slice of tech companies—AI-related companies—are far outperforming others. While not every tech startup has AI software or infrastructure as their core offering, most can benefit from using AI to revise their playbook and become more attractive to investors.

Unlocking Growth Potential with AI

While overall tech startup investment has slowed, the AI sector burns bright. This presents an opportunity for companies that strategically leverage AI, not just as a buzzword but as a tool for genuine growth and differentiation. Imagine a future where AI-powered insights unlock unprecedented efficiency, customer engagement and a paradigm shift in value creation. This isn’t just about weathering the current storm of reduced access to capital; it’s about emerging stronger, ready to lead the next wave of tech innovation.

Here's how to navigate the AI frontier and unlock its potential:

  1. Understand that data is the foundation of AI success. AI is powerful, but it’s not magic. It thrives on high-quality, interconnected data. Before diving into AI initiatives, companies must assess their data health. Is it structured in a way that AI can understand? Does it go beyond raw numbers to capture context and meaning—like customer sentiment alongside sales figures? Rethinking data infrastructure is often the crucial first step.
  1. Focus on amplifying strengths, not reinventing the wheel. The allure of AI can tempt companies into pursuing radical reinvention. However, a more effective strategy is to leverage AI to enhance existing strengths and address core customer needs. Why do customers choose your company? How can AI supercharge your value proposition? Consider Reddit’s strategic approach: They didn’t overhaul their platform before their 2024 IPO. Instead, they showcased the value of their vast online communities as fertile ground for AI development, leading to a remarkable first-day stock surge of 48 percent.

  2. Use AI as a customer-centric force multiplier. Companies with a deep understanding of their customer base are primed for AI success. By integrating AI into the very core of their product or service—the reason customers choose them—they can create a decisive competitive advantage based on delivering tangible customer value.

From Incremental Gains to Transformative Growth

This practical, customer-centric approach has the potential to help companies generate immediate growth while laying the foundation for future reinvention. By leveraging AI to optimize operations, deepen customer relationships, and redefine industry paradigms, late-state tech startups can not only survive but thrive in a dynamic market. The future belongs to those who embrace AI not as a destination but as a continuous journey of innovation and growth.

------

Hong Ogle is the president of Bank of America Houston. Rodrigo Ortiz Gomez is a market executive in Bank of America’s Transformative Technology Banking Group as well as the national software banking lead for the Global Commercial Bank.

Houston joint venture secures $5.2M for AI-powered methane tracking tech

Fresh Funds

Houston-based Envana Software Solutions has received more than $5.2 million in federal and non-federal funding to support the development of technology for the oil and gas sector to monitor and reduce methane emissions.

Thanks to the work backed by the new funding, Envana says its suite of emissions management software will become the industry's first technology to allow an oil and gas company to obtain a full inventory of greenhouse gases.

The funding comes from a more than $4.2 million grant from the U.S. Department of Energy (DOE) and more than $1 million in non-federal funding.

“Methane is many times more potent than carbon dioxide and is responsible for approximately one-third of the warming from greenhouse gases occurring today,” Brad Crabtree, assistant secretary at DOE, said in 2024.

With the funding, Envana will expand artificial intelligence (AI) and physics-based models to help detect and track methane emissions at oil and gas facilities.

“We’re excited to strengthen our position as a leader in emissions and carbon management by integrating critical scientific and operational capabilities. These advancements will empower operators to achieve their methane mitigation targets, fulfill their sustainability objectives, and uphold their ESG commitments with greater efficiency and impact,” says Nagaraj Srinivasan, co-lead director of Envana.

In conjunction with this newly funded project, Envana will team up with universities and industry associations in Texas to:

  • Advance work on the mitigation of methane emissions
  • Set up internship programs
  • Boost workforce development
  • Promote environmental causes

Envana, a software-as-a-service (SaaS) startup, provides emissions management technology to forecast, track, measure and report industrial data for greenhouse gas emissions.

Founded in 2023, Envana is a joint venture between Houston-based Halliburton, a provider of products and services for the energy industry, and New York City-based Siguler Guff, a private equity firm. Siguler Gulf maintains an office in Houston.

“Envana provides breakthrough SaaS emissions management solutions and is the latest example of how innovation adds to sustainability in the oil and gas industry,” Rami Yassine, a senior vice president at Halliburton, said when the joint venture was announced.

---

This story originally appeared on our sister site, EnergyCapitalHTX.com